Par launches authorized generic version of AstraZeneca heart drug

Share this article:
Par Pharmaceuticals said it began shipping an authorized generic version of AstraZeneca beta blocker Toprol-XL. The announcement followed the launch of a 25-mg generic version of metoprolol in the US by Eon Labs, part of Sandoz. Par’s authorized generic also is being distributed in a 25-mg dosage, a size which accounts for about 20% of Toprol-XL US sales, AZ said. Toprol-XL had $838.9 million in sales during the first six months of 2006 and $1.49 billion in sales in 2005, according to IMS Health. An extended-release pill whose patent expires in September 2007, Toprol-XL’s patent was deemed invalid earlier this year in litigation involving KV Pharmaceutical, Andrx Pharmaceuticals, Andrx Corp. and Eon Labs Manufacturing. AZ appealed that decision and, notwithstanding its deal with Par, said it will continue to sell branded Toprol-XL in the US.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.